-transparent.png){kind=logo}
The cases are presented of 4 hydantreated epileptic patients developing malignant lymphomas (1 Hodgkin's lymphoma). The duration of the hydantoin therapy ranged from 7 to 23 years. There was no evidence of an allergic drug reaction, with the exception of slight blood eosinophilia. Prior to the lymphoma one patient exhibited leukopenia and a second thrombocytopenia. Hydantoins were discontinued in 3 cases but the lymphomas never disappeared spontaneously and only once did tumor progression came to a stillstand. Two patients were successfully treated with either chemo- or radiotherapy. Possible correlations between the documented immunosuppressive action of hydantoin derivatives and tumor induction are discussed. Malignant lymphomas may be sequelae of long-term hydantoin therapy and are not always preceded by the well-known reversible hydantoin lymphadenopathy.
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
April 1949,
Wiener klinische Wochenschrift,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
January 1948,
Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
April 1948,
Wiener medizinische Wochenschrift (1946),
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
May 1970,
Archives of neurology,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
September 1966,
Praxis,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
November 1973,
Munchener medizinische Wochenschrift (1950),
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
March 1950,
Der Nervenarzt,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
July 1973,
Munchener medizinische Wochenschrift (1950),
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
August 1948,
The Journal of nervous and mental disease,
W F Jungi, and
H J Senn, and
M Stanisic, and
R Rösli
December 1954,
Arzneimittel-Forschung,
